Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against DexCom, Inc. on behalf of shareholders who purchased securities between July 26, 2024, and September 17, 2025, alleging that the company misled investors regarding its business operations [1][2]. Allegations - The lawsuit claims that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [3]. - It is alleged that the enhancements to the G7 device were overstated, and the company downplayed the severity of issues related to the G7 devices [3]. - The lawsuit suggests that these actions increased DexCom's risk of regulatory scrutiny and potential legal, reputational, and financial harm [3]. - Investors reportedly suffered damages when the true details about the devices were revealed [3]. Next Steps for Shareholders - Shareholders wishing to serve as lead plaintiffs must file motions with the court by December 29, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. About Rosen Law Firm - Rosen Law Firm is recognized for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].